BACKGROUND: Systemic alterations in arginine bioavailability occur in heart failure (HF) patients with more advanced myocardial dysfunction and poorer clinical outcomes, and they improve with beta-blocker therapy. METHODS AND RESULTS: We measured fasting plasma levels of L-arginine and related biogenic amine metabolites in 138 stable symptomatic HF patients with left ventricular ejection fraction ≤35% and comprehensive echocardiographic evaluation. Long-term adverse clinical outcomes (death and cardiac transplantation) were followed for 5 years. Lower global arginine bioavailability ratio (GABR; ratio of L-arginine to L-ornithine + L-citrulline) was associated with higher plasma natriuretic peptide levels, more advanced left ventricular diastolic dysfunction, and more severe right ventricular systolic dysfunction (all P < .001). Patients taking beta-blockers had significantly higher GABR than those not taking beta-blockers (0.86 [interquartile range (IQR) 0.68-1.17] vs 0.61 [0.44-0.89]; P < .001). Subjects with higher GABR experienced fewer long-term adverse clinical events (hazard ratio 0.61 [95% confidence interval 0.43-0.84]; P = .002). In an independent beta-blocker naïve patient cohort, GABR increased following long-term (6 month) beta-blocker therapy (0.89 [IQR 0.52-1.07] to 0.97 [0.81-1.20]; P = .019). CONCLUSIONS: In patients with chronic systolic heart failure, diminished global L-arginine bioavailability is associated with more advanced myocardial dysfunction and poorer long-term adverse clinical outcomes. GABR levels improved with beta-blocker therapy.
BACKGROUND: Systemic alterations in arginine bioavailability occur in heart failure (HF) patients with more advanced myocardial dysfunction and poorer clinical outcomes, and they improve with beta-blocker therapy. METHODS AND RESULTS: We measured fasting plasma levels of L-arginine and related biogenic amine metabolites in 138 stable symptomatic HF patients with left ventricular ejection fraction ≤35% and comprehensive echocardiographic evaluation. Long-term adverse clinical outcomes (death and cardiac transplantation) were followed for 5 years. Lower global arginine bioavailability ratio (GABR; ratio of L-arginine to L-ornithine + L-citrulline) was associated with higher plasma natriuretic peptide levels, more advanced left ventricular diastolic dysfunction, and more severe right ventricular systolic dysfunction (all P < .001). Patients taking beta-blockers had significantly higher GABR than those not taking beta-blockers (0.86 [interquartile range (IQR) 0.68-1.17] vs 0.61 [0.44-0.89]; P < .001). Subjects with higher GABR experienced fewer long-term adverse clinical events (hazard ratio 0.61 [95% confidence interval 0.43-0.84]; P = .002). In an independent beta-blocker naïve patient cohort, GABR increased following long-term (6 month) beta-blocker therapy (0.89 [IQR 0.52-1.07] to 0.97 [0.81-1.20]; P = .019). CONCLUSIONS: In patients with chronic systolic heart failure, diminished global L-arginine bioavailability is associated with more advanced myocardial dysfunction and poorer long-term adverse clinical outcomes. GABR levels improved with beta-blocker therapy.
Authors: G A Haywood; P S Tsao; H E von der Leyen; M J Mann; P J Keeling; P T Trindade; N P Lewis; C D Byrne; P R Rickenbacher; N H Bishopric; J P Cooke; W J McKenna; M B Fowler Journal: Circulation Date: 1996-03-15 Impact factor: 29.690
Authors: R D Bernstein; X Zhang; G Zhao; P Forfia; J Tuzman; F Ochoa; M Ochoa; T Vogel; T H Hintze Journal: Nitric Oxide Date: 1997-10 Impact factor: 4.427
Authors: James O O'Neill; Patrick M McCarthy; Richard C Brunken; Tiffany Buda; Katherine Hoercher; James B Young; Randall C Starling Journal: J Card Fail Date: 2004-06 Impact factor: 5.712
Authors: Richard W Troughton; David L Prior; Jeremy J Pereira; Maureen Martin; Annette Fogarty; Annitta Morehead; Timothy G Yandle; A Mark Richards; Randall C Starling; James B Young; James D Thomas; Allan L Klein Journal: J Am Coll Cardiol Date: 2004-02-04 Impact factor: 24.094
Authors: Claudia R Morris; Hae-Young Kim; Elizabeth S Klings; John Wood; John B Porter; Felicia Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Kathryn Hassell; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Sandra Larkin; Jung H Suh; Elliott P Vichinsky; Frans A Kuypers Journal: Br J Haematol Date: 2015-04-24 Impact factor: 6.998
Authors: David E Lanfear; Joseph J Gibbs; Jia Li; Ruicong She; Christopher Petucci; Jeffrey A Culver; W H Wilson Tang; Yigal M Pinto; L Keoki Williams; Hani N Sabbah; Stephen J Gardell Journal: JACC Heart Fail Date: 2017-11 Impact factor: 12.035
Authors: Brian S Finkelman; Mary Putt; Teresa Wang; Le Wang; Hari Narayan; Susan Domchek; Angela DeMichele; Kevin Fox; Jennifer Matro; Payal Shah; Amy Clark; Angela Bradbury; Vivek Narayan; Joseph R Carver; W H Wilson Tang; Bonnie Ky Journal: J Am Coll Cardiol Date: 2017-07-11 Impact factor: 24.094
Authors: Unnikrishnan M Chandrasekharan; Zeneng Wang; Yuping Wu; W H Wilson Tang; Stanley L Hazen; Sihe Wang; M Elaine Husni Journal: Arthritis Res Ther Date: 2018-06-08 Impact factor: 5.156